SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
12
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Nobilis Health Corporation – HLTH

NEW YORK, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nobilis Health Corporation (“Nobilis” or the “Company”) (NYSEAMERICAN: HLTH). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Nobilis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here to join a class action]

On August 2, 2018, Nobilis reported reduced revenue for the second quarter of 2018, citing a $2.4 million adjustment to its accounts receivable. On this news, Nobilis’s stock price fell $0.20 per share, more than 17%, to close at $0.95 per share on August 2, 2018.

On November 9, 2018, Nobilis reported that it is “re-evaluating the Net Realizable Value on its Accounts Receivable and intends to make a significant adjustment to the carrying value of accounts receivable, primarily on out of network claims greater than 365 days old.” Accordingly, Nobilis filed for additional time to file its quarterly report on Form 10-Q for the period ended September 30, 2018 while the Company and its auditor completed their review of Nobilis’s financial statements. On this news, Nobilis’s stock price fell $0.18 per share, more than 25%, to close at $0.52 per share on November 12, 2018.

Then, on November 15, 2018, Nobilis announced that it had received notice from the New York Stock Exchange (“NYSE”) that the Company is not in compliance with the NYSE’s continued listing requirements due to its failure to timely file its 10-Q. Following this news, Nobilis’s stock price fell $0.07 per share, more than 12%, to close at $0.48 per share on November 16, 2018.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com .

CONTACT: Robert S. Willoughby Pomerantz LLP rswilloughby@pomlaw.com 888-476-6529 ext. 9980

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Qifu Technology Transitions to Qfin Holdings and New Strategies

Updated Category News Views 308

Leadership Changes at Qifu Technology Recently, Qifu Technology, Inc. (NASDAQ: QFIN; HKEx: 3660) held its annual general meeting where shareholders adopted key resolutions that will shape the company’s future. One of the notable changes is the rebranding of the company from Qifu Technology, Inc. to Qfin Holdings, Inc. This transition reflects the ambitious growth...

Continue Reading
Luokung's Journey to Nasdaq Compliance and Future Prospects

Updated Category News Views 47

Luokung Completes Compliance with Nasdaq Regulations Luokung Technology Corp. (NASDAQ: LKCO) has exciting news regarding its compliance status with Nasdaq. Recently, the Nasdaq Stock Market notified the company that it has successfully met the minimum bid price requirement. This is a significant development for Luokung, highlighting its positive performance in the stock...

Continue Reading
Qubrid AI Forms Alliance with ASI for Advanced AI Solutions

Updated Category News Views 157

Qubrid AI Partners with ASI for Enhanced Distribution Qubrid AI, a pioneer in enterprise AI technologies, has recently established a distribution agreement with ASI Corporation, a respected technology distributor. This collaboration aims to enhance market access for Qubrid AI's state-of-the-art AI Controller software and high-performance GPU Appliances. Expanding Access...

Continue Reading
Bexion Pharmaceuticals Secures Grant to Propel BXQ-350 Research

Updated Category News Views 198

Bexion Pharmaceuticals Receives Michael J. Fox Foundation Grant Bexion Pharmaceuticals, Inc., a dedicated clinical-stage biopharmaceutical company, has received a substantial grant to support its innovative research initiatives. This grant, awarded by The Michael J. Fox Foundation for Parkinson's Research, amounts to $1.4 million and will specifically fund the preclinical...

Continue Reading
Class Action Alert: Investors of James Hardie Should Act Soon

Updated Category News Views 98

Class Action Alert for James Hardie Industries PLC Investors Attention to all investors of James Hardie Industries PLC (NYSE: JHX)! If you're among those who purchased James Hardie common stock or American Depositary Shares, this is a critical time for you. Recent developments have unveiled a class action lawsuit that demands immediate attention. This action is initiated...

Continue Reading